RxDoctor Payments Data

Neil Goyal, MD

Cardiovascular Disease · Clifton, NJNPI 1275559718

Payments from drug & device makers

$1,745in general payments, 2019–2025

Across 16 payments — averaging $109.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$965
  • Abiomed$298
  • Boston Scientific$123
  • Amgen$121
  • Pfizer$121
  • Penumbra, Inc.$102
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$1,745100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)8$965
Abiomed3$298
Boston Scientific1$123
Amgen1$121
Pfizer1$121
Penumbra, Inc.1$102
Johnson & Johnson1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,745 in reported general payments places this provider in the 35th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$371,485
Medicare patients
1,096
Services billed
4,211

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban323$371,909
EntrestoSacubitril/Valsartan103$141,105
Repatha SureclickEvolocumab112$113,913
XareltoRivaroxaban55$69,357
FarxigaDapagliflozin Propanediol51$66,636
MultaqDronedarone Hcl29$42,772
Praluent PenAlirocumab21$21,611
JardianceEmpagliflozin17$14,637
Rosuvastatin Calcium695$12,756
BrilintaTicagrelor25$12,298
Ezetimibe223$6,583
Atorvastatin Calcium573$6,302
Metoprolol Succinate364$5,857
Irbesartan189$5,333
Amlodipine Besylate494$3,637

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$121$371,909323 claims
Johnson & JohnsonXarelto$15$69,35755 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Clifton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →